BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholders, At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below. Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadl

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode's request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D). The listing standards of issue included the bid price requirement in Nasdaq Listing Rule 5550(a)(2)

The clinical trial Safety Review Committee (SRC) approved opening of Cohort 2 after review of safety data from the three patients comprising Cohort 1No significant safety or dose limiting toxicities have been reported in Cohort 1Patients are currently being evaluated for eligibility in Cohort 2TTX-MC138 is a therapeutic candidate based on microRNAmicroRNA technology was recognized with the 2024 Nobel Prize in Physiology and MedicineTransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA

Patients currently remain on study for continued treatment with TTX-MC138  No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system, is designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancersmicroRNA technology was recognized with the 2024 Nobel Prize in Physiology and MedicineTransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced tha

Two patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancerTTX-MC138 is an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancersPhase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announc

BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, in collaboration with Michigan State University, published an article in the journal Oncotarget titled, Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties. The article was published on August 26, 2024. The study was led by Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean of the School of Medicine at Michigan State University and scientific co-founder of TransCode. In this study, the authors show that stem-like breast cancer cells

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors. The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138.

Two clinical trial sites activatedPatient enrollment expected this quarterTrial designed to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial sites have been activated with patient enrollment expected to begin during the current quarter. TransCode may activate a total of up to five clinical trial sites, all of which are expected to be activate

BOSTON, July 24, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigati

BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), ("TransCode" or the "Company"), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $0.30 per share, for expected gross proceeds of $3,000,000, before deducting placement agent commissions and offering expenses. All of the shares of common stock are being offered by the Company. The offering is expected to close on July 24, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds fr

10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

DEF 14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

PRE 14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios.  He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. "Dr. Slack is one of the most preeminent scientists in the field of small noncoding RNA," commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. "Having pioneered pivotal studies proving that microRNAs drive oncogenesis and represent critical targets for the treatment of cancer, his guidance will prove indispensable as TransCode enters the clinical phase of development." Dr. Slack is the Shields Warren Mallinckrodt Profe

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4/A - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

- SEC Filing

U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday. The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&P 500 also rose, gaining, 0.14% to 5,572.07. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline Coca-Cola Company (NYSE:KO) reported better-than-expected second-quarter results and raised its guidance. The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4

Transcode Therapeutics Inc (NASDAQ:RNAZ) shares are trading lower by 62% to $0.30 during Tuesday’s session after the company announced pricing of its public offering. The public offering of 10 million shares of its common stock will be at $0.30 per share, aiming to raise $3 million before deducting expenses. The offering is set to close on July 24, pending usual conditions. The funds will be used for product development, including clinical trials for TTX-MC138, their lead therapeutic candidate, and related studies as well as for general corporate purposes. Read Also: Veteran Wall Street Investor Downplays Recession Odds: ‘Current Bull Market Has More Support From Earnings’ Shoul

Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.09% to 40,452.70 while the NASDAQ rose 0.62% to 18,119.84. The S&P 500 also rose, gaining, 0.32% to 5,582.32. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 1% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline GE Aerospace (NYSE:GE) reported better-than-expected second-quarter earnings and raised its FY24 outlook. GE Aerospace reported second-quarter 2024 adjusted revenue growth of 4% year-over-year to

U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded up 0.01% to 40,421.01 while the NASDAQ rose 0.19% to 18,041.10. The S&P 500 also rose, gaining, 0.18% to 5,574.56. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.8% on Tuesday. In trading on Tuesday, utilities shares fell by 0.5%. Top Headline General Motors Company (NYSE:GM) reported better-than-expected second-quarter earnings and raised its guidance. General Motors reported a fiscal second-quarter 202

Shares of SAP SE (NYSE:SAP) rose sharply in today's pre-market trading after the company reported second-quarter financial results. SAP reported quarterly earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro. SAP shares gained 5.9% to $212.34 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Nature’s Miracle Holding Inc. (NASDAQ:NMHI) rose 183.4% to $0.9779 in pre-market trading after fal

The Company intends to use the net proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes.